Pentoxifylline treatment in severe acute pancreatitis: A pilot, double-blind, placebo-controlled, randomized trial

Santhi Swaroop Vege, Tegpal Atwal, Yan Bi, Suresh T Chari, Magdalen A. Clemens, Felicity T Enders

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

In acute pancreatitis (AP) tumor necrosis factor-α mediates multi-organ failure; in animal models its blockade with pentoxifylline ameliorates AP. The efficacy of pentoxifylline in predicted severe AP (pSAP) was tested in a double-blinded, randomized, control trial. Twenty-eight patients with pSAP were randomized within 72 hours of diagnosis to pentoxifylline or placebo. Baseline characteristics were similar in both groups. The pentoxifylline group had fewer intensive care unit admissions and shorter intensive care unit and hospital stays of longer than 4 days (all P <.05). Patients receiving pentoxifylline had no adverse effects. Pentoxifylline within 72 hours of pSAP is safe; a larger study of pentoxifylline in AP is needed to confirm efficacy.

Original languageEnglish (US)
Pages (from-to)318-320.e3
JournalGastroenterology
Volume149
Issue number2
DOIs
StatePublished - Aug 1 2015

Fingerprint

Pentoxifylline
Pancreatitis
Randomized Controlled Trials
Placebos
Therapeutics
Intensive Care Units
Length of Stay
Animal Models
Tumor Necrosis Factor-alpha

Keywords

  • IL6
  • IL8
  • Pentoxifylline
  • Tumor Necrosis Factor-α

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Pentoxifylline treatment in severe acute pancreatitis : A pilot, double-blind, placebo-controlled, randomized trial. / Vege, Santhi Swaroop; Atwal, Tegpal; Bi, Yan; Chari, Suresh T; Clemens, Magdalen A.; Enders, Felicity T.

In: Gastroenterology, Vol. 149, No. 2, 01.08.2015, p. 318-320.e3.

Research output: Contribution to journalArticle

@article{1db391993327462c9f6f3bfdca16cf08,
title = "Pentoxifylline treatment in severe acute pancreatitis: A pilot, double-blind, placebo-controlled, randomized trial",
abstract = "In acute pancreatitis (AP) tumor necrosis factor-α mediates multi-organ failure; in animal models its blockade with pentoxifylline ameliorates AP. The efficacy of pentoxifylline in predicted severe AP (pSAP) was tested in a double-blinded, randomized, control trial. Twenty-eight patients with pSAP were randomized within 72 hours of diagnosis to pentoxifylline or placebo. Baseline characteristics were similar in both groups. The pentoxifylline group had fewer intensive care unit admissions and shorter intensive care unit and hospital stays of longer than 4 days (all P <.05). Patients receiving pentoxifylline had no adverse effects. Pentoxifylline within 72 hours of pSAP is safe; a larger study of pentoxifylline in AP is needed to confirm efficacy.",
keywords = "IL6, IL8, Pentoxifylline, Tumor Necrosis Factor-α",
author = "Vege, {Santhi Swaroop} and Tegpal Atwal and Yan Bi and Chari, {Suresh T} and Clemens, {Magdalen A.} and Enders, {Felicity T}",
year = "2015",
month = "8",
day = "1",
doi = "10.1053/j.gastro.2015.04.019",
language = "English (US)",
volume = "149",
pages = "318--320.e3",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Pentoxifylline treatment in severe acute pancreatitis

T2 - A pilot, double-blind, placebo-controlled, randomized trial

AU - Vege, Santhi Swaroop

AU - Atwal, Tegpal

AU - Bi, Yan

AU - Chari, Suresh T

AU - Clemens, Magdalen A.

AU - Enders, Felicity T

PY - 2015/8/1

Y1 - 2015/8/1

N2 - In acute pancreatitis (AP) tumor necrosis factor-α mediates multi-organ failure; in animal models its blockade with pentoxifylline ameliorates AP. The efficacy of pentoxifylline in predicted severe AP (pSAP) was tested in a double-blinded, randomized, control trial. Twenty-eight patients with pSAP were randomized within 72 hours of diagnosis to pentoxifylline or placebo. Baseline characteristics were similar in both groups. The pentoxifylline group had fewer intensive care unit admissions and shorter intensive care unit and hospital stays of longer than 4 days (all P <.05). Patients receiving pentoxifylline had no adverse effects. Pentoxifylline within 72 hours of pSAP is safe; a larger study of pentoxifylline in AP is needed to confirm efficacy.

AB - In acute pancreatitis (AP) tumor necrosis factor-α mediates multi-organ failure; in animal models its blockade with pentoxifylline ameliorates AP. The efficacy of pentoxifylline in predicted severe AP (pSAP) was tested in a double-blinded, randomized, control trial. Twenty-eight patients with pSAP were randomized within 72 hours of diagnosis to pentoxifylline or placebo. Baseline characteristics were similar in both groups. The pentoxifylline group had fewer intensive care unit admissions and shorter intensive care unit and hospital stays of longer than 4 days (all P <.05). Patients receiving pentoxifylline had no adverse effects. Pentoxifylline within 72 hours of pSAP is safe; a larger study of pentoxifylline in AP is needed to confirm efficacy.

KW - IL6

KW - IL8

KW - Pentoxifylline

KW - Tumor Necrosis Factor-α

UR - http://www.scopus.com/inward/record.url?scp=84938150078&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938150078&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2015.04.019

DO - 10.1053/j.gastro.2015.04.019

M3 - Article

C2 - 26112745

AN - SCOPUS:84938150078

VL - 149

SP - 318-320.e3

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 2

ER -